9 completed, 5 terminated, 3 unknown, 2 recruiting. 8 Phase 3, 6 Phase 4, 3 Not applicable, 3 Phase 2, 1 Early Phase 1.
Follow Cloxacillin: new trials by email Literature Review of Cloxacillin trials Research Report on Cloxacillin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Antibiotic Tissue Penetration and Tissue Response in Head and Neck Infection and Reconstructive Surgery Cefuroxime, Dicloxacillin, Cloxacillin - Surgical Wound Infection, Neck Infection | Phase 4 | Not yet recruiting | Tejs Ehlers Klug | 16 | 2026-10-01 | 2026-10-26 |
| Continuous Antibiotic Infusion In Children Benzylpenicillin - Infection | Phase 3 | Recruiting | Tampere University Hospital | 150 | 2026-04-21 | 2026-05-08 |
| Comparison of Cloxacillin and Benzylpenicillin in Penicillin Susceptible S. Aureus Bacteraemia Penicillin G_1200mg, cloxacillin - Staphylococcus Aureus Bacteraemia, Staphylococcal Bacteraemia | Phase 4 | Recruiting | Region Skane | 420 | 2025-03-10 | 2026-04-30 |
| Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia Tab. Trimethoprim-sulfamethoxazole, Tab. Clindamycin, Tab. Cephalexin, or Tab. Linezolid, IV Cloxacillin, IV Cefazolin, IV Vancomycin, or IV Ceftaroline - Staphylococcus Aureus Bacteremia | Phase 3 | Unknown | Clinical Research Centre, Malaysia | 290 | 2024-06-28 | 2024-07-05 |
| Ceftriaxone as Home IV for Staph Infections Ceftriaxone, Usual Antibiotics (Cloxacillin, Cefazolin, Daptomycin) - Staphylococcal Infections, Osteomyelitis | Phase 4 | Unknown | Vancouver Island Health Authority | 310 | 2019-07-11 | 2019-10-28 |
| Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia Cloxacillin, Cefazolin - Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 315 | 2018-09-05 | 2025-11-24 |
| Combination Antibiotic Therapy for Methicillin Resistant Staphylococcus Aureus Infection Beta-Lactam - Methicillin-Resistant Staphylococcus Aureus | Phase 3 | Terminated | Menzies School of Health Research | 358 | 2015-08-26 | 2018-12-19 |
| A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial Telavancin, Vancomycin, Daptomycin - Bacteremia | Phase 3 | Terminated | Cumberland Pharmaceuticals | 121 | 2014-12-01 | 2020-02-17 |
| Patients Response to Early Switch To Oral:Osteomyelitis Study oral antibiotics, intravenous antibiotics - Osteomyelitis | Early Phase 1 | Terminated | Julio Ramirez | 11 | 2014-03-06 | 2021-04-06 |
| Staphylococcus Aureus Bacteremia Antibiotic Treatment Options Trimethoprim-Sulfamethoxazole, Clindamycin, Linezolid - Staphylococcus Aureus Infection | Phase 3 | Completed | Heinrich-Heine University, Duesseldorf | 215 | 2013-12-01 | 2020-05-27 |
| Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus. Cloxacilin, Cloxacillin, Levofloxacin - Staphylococcus | Phase 3 | Terminated | Fundación Pública Andaluza Progreso y Salud | 1 | 2013-05-01 | 2015-08-07 |
| Treatment Algorithm to Reduce the Use of Vancomycin in Adults With Blood Stream Infection Vancomycin - Bacteremia | Phase 2 | Completed | Duke University | 509 | 2011-02-01 | 2018-01-05 |
| Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment Vancomycin, Daptomycin, Semi-Synthetic Penicillin - Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia | Phase 4 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 92 | 2010-04-19 | 2018-09-05 |
| Study to Compare Efficacy and Safety of Daptomycin in Elderly Patients With Complicated Skin and Soft Tissue Infections Daptomycin, Vancomycin or Semi-Synthetic Penicillins (SSPs) - Infections | Phase 3 | Completed | Novartis Pharmaceuticals | 120 | 2010-03-01 | 2012-07-13 |
| Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections Daptomycin, Standard of Care (SOC) - Skin Diseases, Infectious | Phase 4 | Completed | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 396 | 2008-07-23 | 2018-09-05 |
| Use of Probiotic Lactobacilli for the Treatment of Lactational Mastitis Lactobacillus salivarius HN6, Lactobacillus reuteri CR20, Lactobacillus fermentum LC40 - Mastitis | Phase 2 / Phase 3 | Completed | Universidad Complutense de Madrid | 300 | 2008-07-01 | 2009-05-25 |
| Cloxacillin as Prevention of Double Lumen Infection in Hemodialysis Patients cloxacillin, heparin - Double Lumen Infection, Hemodialysis | Not applicable | Completed | Shiraz University of Medical Sciences | 100 | 2008-01-01 | 2009-04-21 |
| Rifampin Combination Therapy Versus Monotherapy in Early Staphylococcal Infections After Total Hip and Knee Arthroplasty Rifampin-combination therapy, Monotherapy - Prosthesis-related Infections, Staphylococcal Infections | Phase 4 | Unknown | Oslo University Hospital | 100 | 2006-04-01 | 2013-06-27 |
| Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia Telavancin, Vancomycin, nafcillin, oxacillin, or cloxacillin - Gram-Positive Bacterial Infections | Phase 2 | Completed | Cumberland Pharmaceuticals | 60 | 2003-08-01 | 2019-01-16 |
| Once-Daily Amikacin Plus Cloxacillin in Febrile Neutropenic Children cloxacillin and amikacin (once or twice daily dosage) - Neutropenia, Cancer | Not applicable | Completed | Khon Kaen University | 166 | 2002-04-01 | 2005-09-23 |
Staphylococcal Infections (6) · Bacteremia (5) · Osteomyelitis (3) · Infections (2) · Sepsis (2) · Abscess (1) · Arthritis, Infectious (1) · Breast Feeding (1) · Cellulitis (1) · Central Nervous System Infections (1) · Disease Susceptibility (1) · Febrile Neutropenia (1) · Fever (1) · Gram-Positive Bacterial Infections (1) · Mastitis (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · Cumberland Pharmaceuticals (2) · Assistance Publique - Hôpitaux de Paris (1) · Clinical Research Centre, Malaysia (1) · Duke University (1) · Fundación Pública Andaluza Progreso y Salud (1) · Heinrich-Heine University, Duesseldorf (1) · Julio Ramirez (1) · Khon Kaen University (1) · Menzies School of Health Research (1) · Novartis Pharmaceuticals (1) · Oslo University Hospital (1) · Region Skane (1) · Shiraz University of Medical Sciences (1) · Tampere University Hospital (1)
United States (6) · Spain (5) · France (2) · Germany (2) · Australia (1) · Austria (1) · Canada (1) · Denmark (1) · Finland (1) · India (1) · Iran (1) · Israel (1) · Italy (1) · Malaysia (1) · Netherlands (1)
Achim J Kaasch, MD (1) · David Seligson, MD (1) · Ellie Hershberger (1) · Ellie Hershberger, Pharm.D. (1) · Eric Partlow, MD, FRCPC (1) · Finnur Snorrason, M.D, Ph.D (1) · G. Ralph Corey, MD (1) · Joshua Davis, MBBS, FRACP (1) · Julio Ramirez, MD (1) · Malin Hagstrand Aldman, PhD, MD (1) · Steven Tong, MBBS, FRACP (1) · Tejs Ehlers Klug, MD, DMSc (1)
PMID 15276398, PMID 15840453, PMID 19588358, PMID 20455694, PMID 22530208, PMID 24880136, PMID 24884578, PMID 26452342, PMID 27029920, PMID 28202770, PMID 30173161, PMID 30264119, PMID 32044943, PMID 32051007, PMID 32859235, PMID 38244557, PMID 41115439, PMID 4902833, PMID 8948280
2009 (1), 2023 (1), 2025 (1)